ArticleAntimicrobial agents and chemotherapy2006
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Pharmacokinetic and Pharmacodynamic Evaluation of a Weight-Based Dosing Regimen of Cefoxitin for Perioperative Surgical Prophylaxis in Obese and Morbidly Obese Patients.Antimicrobial agents and chemotherapy · 2016Trial
- Obesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.Surgical infections · 2016Trial
- Doripenem Treatment during Continuous Renal Replacement Therapy.Antimicrobial agents and chemotherapy · 2015Trial
- Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.Antimicrobial agents and chemotherapy · 2010Trial
- Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections.Antimicrobial agents and chemotherapy · 2023Article
- Clinical Outcomes with Ertapenem for Pneumonia in Obese versus Nonobese Patients.Antimicrobial agents and chemotherapy · 2022Article
- Model-Informed Precision Dosing of Antibiotics in Osteoarticular Infections.Infection and drug resistance · 2022Review
- Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem againstAntimicrobial agents and chemotherapy · 2020Article
- Article
- Impact of High Body Weight on Mortality in Critically Ill Patients Receiving Meropenem for Pneumonia.Cureus · 2019Article
- Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.Antimicrobial agents and chemotherapy · 2019Article
- Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations.European journal of clinical pharmacology · 2019Article
- Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes.Antimicrobial agents and chemotherapy · 2018Article
- Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.Antimicrobial agents and chemotherapy · 2018Article
- The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2017Article
- Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.Antimicrobial agents and chemotherapy · 2017Article
- Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Antimicrobial agents and chemotherapy · 2017Article
- Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250 kg Patient.Case reports in critical care · 2017Article
- Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.Clinical pharmacokinetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known of the effects of obesity on ertapenem drug disposition and pharmacodynamics. Thirty healthy volunteers in three body mass index (BMI) groups (10 per group), normal weight (BMI, 18.5 to 24.9 kg/m2), class I-II obesity (BMI, 30 to 39.9 kg/m2), and class III obesity (BMI, >or=40 kg/m2), were administered a 1-g dose of ertapenem. Serum concentrations were obtained over 24 h. Population pharmacokinetic data were obtained using a nonparametric adaptive grid followed by Monte Carlo simulation to determine the probability of obtaining the free drug exposure targets of the time that the free drug concentration remains above the MIC (fT>MIC) of 20% and 40% for bacteriostatic and maximal bactericidal activity, respectively. Compared to the subjects in the obese groups, area under the concentration-time curve from 0 h to infinity was significantly higher in the normal-weight subjects, whereas the total central compartment volume was higher in the class III obese subjects (P<or=0.05). Achieving a bacteriostatic target of fT>MIC of 20% with a 90% probability was attained at MICs of <or=0.5 microg/ml for normal-weight subjects. Class I-II and class III obese subjects were able to achieve this target only at a MIC of <or=0.25 microg/ml. For maximal bactericidal activity (fT>MIC, 40%), no group attained the target at the 90% probability level at any tested MIC. The results suggest that the standard 1-g ertapenem dose may not provide adequate drug exposure for any body mass index classification for MICs in excess of 0.25 to 0.5 microg/ml.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.